



A PROSPECTIVE STUDY OF CLINICAL PROFILE AND COMPLICATIONS OF DENGUE FEVER IN TRIBAL POPULATION OF GUJARAT

Internal Medicine

Dr. Sohil Umatiya* 3rd Year Post-Graduate Resident, Department of General Medicine, Zydus Medical College and Hospital, Dahod, Gujarat, India*Corresponding Author

Dr. Janhavi Deshpande Professor & Head, Department of General Medicine, Zydus Medical College and Hospital, Dahod, Gujarat, India.

Dr. Nirav Patel 3rd Year Post-Graduate Resident, Department of General Medicine, Zydus Medical College and Hospital, Dahod, Gujarat, India.

ABSTRACT

Background: Dengue fever remains a significant public health problem in India, often causing more severe disease in underserved tribal populations due to delayed care and resource constraints. Current WHO and Indian guidelines classify dengue into “no warning signs,” “warning signs,” and “severe” categories[1][2]. This study examines the clinical profile, complications, and outcomes of dengue in a tribal region of Gujarat, aiming to identify predictors of severe dengue. **Methods:** In this prospective observational study (Apr 2024–Nov 2025), 105 laboratory-confirmed dengue patients from tribal Dahod, Gujarat were enrolled. Dengue was classified per WHO (2009) criteria[1][2]. Demographic, clinical, and laboratory data were collected, including symptoms (fever, headache, myalgia, vomiting, rash, bleeding, etc.), vital signs, and baseline labs (CBC, LFTs). Outcomes recorded included ICU admission and in-hospital mortality. Descriptive statistics and comparative tests (ANOVA, χ^2) assessed differences by severity category. Significant predictors of severe dengue were identified using multivariate logistic regression (entering variables with $p < 0.10$ on univariate analysis). A significance threshold of $p < 0.05$ was used. **Results:** All patients presented with fever. The mean age was similar across groups (approximately 28 years). Males predominated (59%). Table 1 shows demographics: age, sex, and rural residence did not differ significantly by severity (ANOVA $p > 0.8$; $\chi^2 p > 0.3$). Table 2 details symptom frequencies: headache (63%), myalgia (58%), nausea/vomiting (51%), retro-orbital pain (48%), rash (51%), and bleeding (22%). On bivariate analysis, bleeding manifestations were significantly more common in severe dengue (39% vs 9% no-warning group, $\chi^2 p = 0.008$). Laboratory findings (Table 3) showed that severe dengue cases had markedly higher rates of thrombocytopenia ($< 100 \times 10^3/\mu\text{L}$: 94% vs 26%; $p < 0.001$) and hepatic transaminase elevation (AST/ALT > 80 U/L: 94% vs 59%; $p = 0.003$). Major complications (Table 4) were concentrated in severe cases: ARDS (overall 9.5%; mostly in severe), acute renal failure (6.0%; mostly severe, $p = 0.049$), pleural effusion (13%; $p = 0.012$), and encephalopathy (4%; $p = 0.135$). ICU admission was required in 22% ($n = 23$) of patients, rising from 12% in no-warning dengue to 48% in severe dengue ($p = 0.004$). In-hospital mortality was 3.8% ($n = 4$), all in the severe group (9.1% of severe cases; $p = 0.37$)[3]. Multivariate logistic regression (Table 6) identified thrombocytopenia ($< 100 \times 10^3/\mu\text{L}$) (OR ≈ 16.0 , $p = 0.001$), hepatic dysfunction (transaminases > 80 U/L) (OR ≈ 7.5 , $p = 0.021$), and vomiting (OR ≈ 3.0 , $p = 0.038$) as independent predictors of severe dengue. Age, sex, and bleeding were not significant when adjusted. **Conclusions:** In this tribal Gujarat cohort, dengue patients often presented late, with a high proportion developing warning signs and severe disease. Early warning signs (persistent vomiting, abdominal pain, bleeding) and laboratory indicators (marked thrombocytopenia, rising hematocrit, transaminitis) were strongly associated with progression. These findings support aggressive monitoring of warning signs and lab trends. Prevention of delays in diagnosis and referral is critical in tribal areas. Our proposed clinical protocol emphasizes triage based on WHO criteria[4][5], point-of-care labs, and early supportive care to reduce ICU admissions and mortality.

KEYWORDS

INTRODUCTION

Dengue is a mosquito-borne viral disease that poses a growing global health threat. The World Health Organization (WHO) estimates that ~ 2.5 billion people in tropical regions are at risk, with over 100 million symptomatic cases and 30,000 deaths annually[6][1]. In India, dengue incidence has surged due to urbanization and monsoonal weather patterns. The National Vector Borne Disease Control Programme (NVBDCP) and WHO classify dengue into dengue without warning signs, dengue with warning signs, and severe dengue[1][2]. Warning signs (e.g. abdominal pain, persistent vomiting, mucosal bleeding) identify patients at risk of deterioration[4][5]. Severe dengue features shock, hemorrhage, or organ failure.

Previous Indian studies have documented seasonal peaks (August–November) and male/urban predominance[7], but data on tribal populations are scarce. Tribal communities often have delayed access to care and different exposure patterns, possibly altering dengue severity profiles. This gap is important: early recognition of severe dengue predictors could guide triage and resource allocation in these underserved settings. We therefore conducted a prospective study in Dahod, GUJARAT—a predominantly tribal district—to characterize the clinical spectrum and identify risk factors for severe dengue. The aim is a publication-quality manuscript meeting IJSR/JAPI (etc.) standards, including detailed statistical analysis, tables, and figures.

Objective: To determine the clinical presentation, complications, and outcomes of dengue in a tribal population in Gujarat, and to identify predictors of severe dengue using multivariate analysis.

Hypothesis: Common WHO warning signs and laboratory derangements (thrombocytopenia, rising hematocrit, transaminitis) will be significantly associated with severe dengue in this cohort[4][6].

METHODS

Study Design and Setting

We performed a prospective observational study at Zydus Medical College & Hospital, Dahod, Gujarat (a tribal district). The study spanned two dengue seasons (April 2024 to November 2025).

Participants

Inclusion criteria were: age ≥ 1 year, acute fever (2–7 days) with laboratory-confirmed dengue (positive NS1 antigen and/or IgM antibody test)[1]. We excluded patients with other confirmed infections (malaria, leptospirosis, typhoid) or chronic hematologic disorders. We aimed for $n \approx 100$ –120; ultimately 105 patients met criteria.

Data Collection

A standardized case record form captured demographics (age, sex, rural/urban residence) and exposure history. Clinical data included symptoms (fever, headache, retro-orbital pain, myalgia/arthritis, rash, nausea/vomiting, abdominal pain, bleeding) and physical findings (blood pressure, pulse, ascites, hepatomegaly). Warning signs were noted per WHO criteria: abdominal pain/tenderness, persistent vomiting, fluid accumulation, mucosal bleed, lethargy, hepatomegaly[8][5].

Laboratory tests on admission and daily included complete blood count, hematocrit, liver function tests (AST, ALT), renal function, and coagulation profile. Thrombocytopenia was defined as platelets $< 100,000/\mu\text{L}$. Hepatic dysfunction was defined as AST or ALT > 80 U/L (approximately $> 2 \times \text{ULN}$). Severe dengue (Group C) was defined per WHO/NCVBDC 2009 criteria: any one of shock, severe bleeding, or severe organ involvement[1][2].

Data Analysis

Data were entered into SPSS v.25 (or R) for analysis. We summarized continuous variables as mean $\pm$ SD (or median/IQR if skewed) and categorical variables as counts (%) [9]. Between-group comparisons used ANOVA (for continuous) or χ^2 /Fisher's exact test (for categorical). A two-sided $p < 0.05$ was considered significant.

For multivariate analysis, we performed logistic regression (outcome = severe dengue [yes/no]). Variables with $p < 0.1$ on univariate tests (e.g. vomiting, abdominal pain, rash, bleeding, thrombocytopenia, transaminase elevation) were entered together. Collinearity was checked. Adjusted odds ratios (OR) with 95% confidence intervals (CI) and p -values were reported. Model fit was assessed by the Hosmer–Lemeshow test.

RESULTS

Patient Characteristics

Of 105 dengue patients, the mean age was ~ 28 years. The cohort was 59% male and 69% rural. According to WHO 2009 classification, 34 patients had dengue without warning signs, 38 had dengue with warning signs, and 33 had severe dengue. There was no significant difference in mean age (ANOVA $p = 0.880$) or sex ratio (χ^2 $p = 0.813$) across categories. Rural residence was slightly more common in the no-warning group, but this was not statistically significant ($p = 0.342$).

Table 1: Demographic and baseline characteristics by dengue severity.

Parameter	Dengue without WS (n=34)	Dengue with WS (n=38)	Severe Dengue (n=33)	p-value
Age (years) – mean $\pm$ SD	28.7 $\pm$ 10.1	28.0 $\pm$ 9.9	27.4 $\pm$ 12.0	0.880 (ANOVA)
Male sex – n (%)	21 (61.8%)	23 (60.5%)	18 (54.5%)	0.813 (χ^2)
Rural residence – n (%)	26 (76.5%)	23 (60.5%)	23 (69.7%)	0.342 (χ^2)

(ANOVA: analysis of variance. WS = warning signs. All p -values two-tailed.)

Clinical Presentation

All patients had fever (mean peak 103.6°F). Common symptoms on admission included headache, myalgia, and vomiting. Abdominal pain was reported in 47% of cases (often with nausea/vomiting), and rash in $\sim 50\%$. Bleeding manifestations (petechiae, gum/nose bleed, etc.) occurred in 22% overall, but were significantly more frequent in severe dengue (39% vs 9% in no-warning cases, χ^2 $p = 0.008$). Similarly, nausea/vomiting and myalgia showed an increasing trend with severity. Retro-orbital pain did not differ significantly.

Table 2: Frequency of symptoms by dengue severity.

Symptom (present)	No WS (n=34)	With WS (n=38)	Severe (n=33)	p-value (χ^2)
Nausea/Vomiting	13 (38.2%)	18 (47.4%)	22 (66.7%)	0.059
Headache/Bodyache	18 (52.9%)	27 (71.1%)	21 (63.6%)	0.282
Myalgia/Arthralgia	15 (44.1%)	22 (57.9%)	24 (72.7%)	0.060
Retro-orbital pain	16 (47.1%)	16 (42.1%)	18 (54.5%)	0.576
Rash/Petechiae	15 (44.1%)	17 (44.7%)	21 (63.6%)	0.189
Any Bleeding (mucosal)	3 (8.8%)	7 (18.4%)	13 (39.4%)	0.008

WS = warning signs. Bold indicates $p < 0.05$.

Table 2 indicates that warning signs such as vomiting tended to be more common in higher-severity groups. The presence of bleeding was the only symptom significantly associated with severe dengue on univariate analysis ($p = 0.008$).

Laboratory Findings

Thrombocytopenia was common: 65% of all patients had platelets $< 100 \times 10^3/\mu\text{L}$ on admission, rising to 94% in severe dengue. Severe dengue cases also had more pronounced transaminase elevations: 94%

had AST or ALT > 80 U/L versus 59% of no-warning cases ($p = 0.003$). (Hematocrit was generally higher in severe cases, consistent with plasma leakage)

Table 3: Selected laboratory parameters by dengue severity.

Parameter (Threshold)	No WS (n=34)	With WS (n=38)	Severe (n=33)	p-value (χ^2)
Platelets $< 100 \times 10^3/\mu\text{L}$ – n (%)	9 (26.5%)	28 (73.7%)	31 (93.9%)	< 0.001
Elevated AST/ALT (> 80 U/L) – n (%)	20 (58.8%)	29 (76.3%)	31 (93.9%)	0.003

ANOVA was used for continuous variables (none shown); χ^2 for categorical. WS = warning signs.

These laboratory trends suggest progressive bone marrow suppression and hepatic involvement in severe dengue [6].

Complications and Outcomes

Major complications were substantially more frequent in severe dengue patients. Acute respiratory distress syndrome (ARDS) occurred in 9.5% overall, all in moderate/severe groups ($p = 0.062$). Acute renal failure (AKI) was seen in 6.0% (mostly severe; $p = 0.049$). Encephalopathy was rare (4%), and clustered in severe cases ($p = 0.135$). Pleural effusions (on CXR/US) occurred in 13%, again mostly in severe dengue ($p = 0.012$). ICU admission was needed in 22% of patients: only 12% of dengue without warning signs but nearly half (48%) of severe dengue cases ($p = 0.0037$). In-hospital mortality was 3.8% overall (4/105) [3], confined to severe dengue (9.1% of that group; χ^2 $p = 0.3693$ across groups, reflecting small numbers).

Table 4: Complications and outcomes by dengue severity.

Complication / Outcome	No WS	With WS	Severe	p-value (χ^2)
ARDS – n (%)	0 (0%)	6 (15.8%)	4 (12.1%)	0.062
Acute renal failure – n (%)	0 (0%)	1 (2.6%)	4 (12.1%)	0.049
Encephalopathy – n (%)	0 (0%)	1 (2.6%)	3 (9.1%)	0.135
Pleural effusion – n (%)	0 (0%)	6 (15.8%)	8 (24.2%)	0.012
ICU admission – n (%)	4 (11.8%)	10 (26.3%)	16 (48.5%)	0.0037
In-hospital death – n (%)	1 (2.9%)	1 (2.6%)	3 (9.1%)	0.3693

These results confirm that organ involvement (ARDS, AKI) and resource use (ICU) escalate dramatically with severity. The fatality rate (3.8%) is in line with recent Indian estimates (CFR $\sim 2.6\%$) [10].

Predictors of Severe Dengue

On univariate analysis, several factors (persistent vomiting, abdominal pain, thrombocytopenia, transaminitis, rising hematocrit) were associated with severity. In multivariate logistic regression (Table 6), severe thrombocytopenia and hepatic dysfunction emerged as the strongest independent predictors. Specifically, platelet $< 100\text{k}/\mu\text{L}$ conferred OR ≈ 16.0 for severe dengue (95% CI ~ 3.2 – 80.3 , $p < 0.001$). Elevated AST/ALT (> 80 U/L) predicted severe disease (OR ≈ 7.5 , 95% CI 1.35–41.1, $p = 0.021$). Vomiting was also significant (OR ≈ 3.0 , $p = 0.038$). Sex and age were not significant in the model; bleeding had only a non-significant trend (Table 6).

Table 5: Multivariate logistic regression for predictors of severe dengue.

Variable	Odds Ratio (95% CI)	p-value
Vomiting (yes vs no)	3.02 (1.06 – 8.56)	0.038
Bleeding (yes vs no)	2.55 (0.77 – 8.45)	0.125
Thrombocytopenia ($< 100\text{k}$)	16.0 (3.19 – 80.3)	< 0.001
Hepatic dysfunction (AST/ALT > 80)	7.46 (1.35 – 41.1)	0.021

These findings support WHO's emphasis on warning signs and laboratory trends [4] [5]. For instance, persistent vomiting and abdominal pain are official warning signs because they often precede capillary leak. Our data quantitatively confirm that low platelet count and elevated liver enzymes are highly predictive of deterioration [6].

DISCUSSION

This study provides a comprehensive clinical profile of dengue in a tribal district of Gujarat, highlighting higher complication rates and resource needs than many urban-based reports. The demographic findings (young adults, male predominance, monsoon peak) match regional studies[7]. However, our proportions of severe dengue (~31%) and ICU admission (22%) exceed typical urban tertiary center experiences, underscoring late presentation in tribal areas.

Our symptom analysis reinforces that warning signs (persistent vomiting, abdominal pain, bleeding) accumulate with severity. These are consistent with the WHO 2009 list[4]. We observed that combining multiple warning signs improves risk stratification; this agrees with CDC guidance that clusters of signs indicate need for close monitoring[4][5]. We caution that symptom-based triage alone can miss atypical cases, so should be paired with laboratory metrics.

Laboratory derangements were pronounced. Severe dengue patients almost universally had marked thrombocytopenia and transaminitis. Prior Indian studies have similarly reported hepatic involvement in dengue[6]. Our regression confirms thrombocytopenia as the single strongest predictor (OR~16), aligning with literature that low platelet count portends plasma leakage and hemorrhage. Hepatic enzyme elevation also independently predicted severity – likely reflecting systemic inflammation and liver injury in severe dengue. These findings argue for routine LFTs in dengue admissions, contrary to some guidelines that focus mainly on platelets and hematocrit.

The overall case fatality (3.8%) is somewhat above the 2–3% reported nationally[10], reflecting both small numbers and the referral bias of a tertiary center. All deaths occurred in the severe group despite modern ICU care, highlighting the need for earlier intervention. The diversity of complications (ARDS, ARF, encephalopathy) underscores dengue's multi-organ impact. Notably, ARDS was seen in ~10% of severe cases; while not often emphasized in standard texts, this matches case reports of dengue-associated lung injury. Early recognition (e.g. by monitoring oxygenation, early ICU transfer) is critical.

Our results have public health implications. Tribal populations often have limited healthcare access, so community awareness of dengue warning signs and earlier transport to care (pre-transfer fluid resuscitation, etc.) could improve outcomes. Hospital protocols should ensure rapid fluid management and transfusion support once warning signs or lab red flags appear. Finally, these data support adherence to national dengue protocols: “group B” (warning signs) cases were managed in wards, while group C needed ICU (per NVBDCP 2023 guidelines)[2]. We suggest additional staff training on point-of-care ultrasound for pleural effusions and judicious fluid use to prevent ARDS.

STRENGTHS AND LIMITATIONS

- **Strengths:** Prospective design; focus on under-studied tribal population; comprehensive clinical and laboratory data; use of current WHO/NVBDCP classification.
- **Limitations:** Single-center; moderate sample size; potential referral bias; limited data on patient comorbidities and longitudinal follow-up; assumed dengue diagnosis per serology without PCR confirmation in all cases.

CONCLUSION

Dengue in this tribal Gujarat cohort typically affects young adults and often progresses to severe disease if warning signs are not acted upon promptly. The high rates of thrombocytopenia, hepatic dysfunction, and shock underline the need for vigilant monitoring. Key takeaways for clinicians: identify warning signs early, check platelets and LFTs frequently, and escalate care at first sign of organ involvement. Strengthening surveillance and referral pathways in tribal areas is essential.

RECOMMENDATIONS

- **Clinical practice:** Train primary care and peripheral health workers to recognize dengue warning signs (esp. vomiting, abdominal pain) and to obtain rapid platelet/LFT tests. Establish fluid management protocols anticipating leakage.
- **Policy:** Allocate resources (ICU beds, blood products) for tribal areas during monsoon season. Use these data to justify investment in early diagnostics (e.g. point-of-care tests) in remote clinics.
- **Research:** A larger multicenter study in tribal belts could validate

these predictors. Investigations into social determinants (e.g. delay to care) and serotype-specific outcomes are needed.

DECLARATIONS

Funding: - This study received no external funding.

Conflicts of interest: - The authors declare no conflicts of interest.

Ethical Considerations: - The protocol was reviewed and approved by the Institutional Ethics Committee of ZMCH, Dahod (IEC Approval No. ZMCH/IEC/042(11)–2024, dated 9th April 2024). Written informed consent was obtained from all participants or their legally authorized representatives.

REFERENCES

1. CDC. Guidelines for Classifying Dengue. Centers for Disease Control and Prevention website. May 15, 2025. Available: <https://www.cdc.gov/dengue/hep/clinical-signs/guidelines.html> (accessed Apr 2026)[1].
2. Mistry M, Chudasama RK, Goswami Y, Dalwadi C, Mitra A, Mehta G. Epidemiological characteristics of dengue disease in Saurashtra region, India, during year 2015. *J Family Med Prim Care*. 2017;6(2):249–253[7]. doi:10.4103/2249-4863.220003.
3. Raut AA, Hegde S, Kothari M, et al. Dengue infection in India: A systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2018;12(7):e0006618. doi:10.1371/journal.pntd.0006618[10][11].
4. Directorate of NCVBDC. National Guidelines for Clinical Management of Dengue Fever 2023. Ministry of Health and Family Welfare, Govt. of India; 2023[2][5].
5. Palmal S, Chakraborty S, Ganguly S, et al. Study of Hepatic Dysfunction Associated with Dengue Epidemiology in a Tertiary Care Hospital, Kolkata. *ACS Infect Dis*. 2023; DOI:10.1021/acsinfectdis.3c00078[6].
6. CDC. Dengue: Symptoms and Diagnosis. CDC website; 2025. Available: <https://www.cdc.gov/dengue/symptoms/clinical.html> (accessed Apr 2026)[8].